Immunotherapies

Therapy Areas

Drug Classes

Therapy Areas

All Sessions

Resectable NSCLC

Advanced NSCLC

SCLC

Biomarkers

Drug Classes

Targeted Therapies

ADCs

All

FEATURED

ILCS

Webinars

Articles

Industry Sponsored

Featured Sessions

Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC

May 04 2026

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro

From Our Annual Summit

ILCS Sessions

Sep 26 2025

ILCS 2025

Immunotherapies

The Role of IO Added to Chemoradiation in Unresectable Stage III NSCLC

} 28 min

Tailoring IO in Res. NSCLC: Personalized Approaches for Improved Outcomes

} 36 min

Tailoring IO in Resectable NSCLC: Personalized Approaches for Improved Outcomes

} 25 min

J. Remon

Expert Insights

Webinars

Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin

Dec 18 2025

VIRTUAL ROUNDTABLE

Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck

IO in NSCLC by Solange Peters, Jordi Remon, Patrick Forde

Jun 25 2025

VIRTUAL ROUNDTABLE

Advanced NSCLCImmunotherapies

Immunotherapies in NSCLC

} 1h 47 min

P. FordeJ. RemonS. Peters

SCLC by Solange Peters, Giannis Mountzios, Jacob Sands

Jun 17 2025

VIRTUAL ROUNDTABLE

SCLCImmunotherapies

Small Cell Lung Cancer

} 1h 35 min

G. MountziosJ. SandsS. Peters

The Reading Room

Articles & Research

Oct 02 2026

RESEARCH

Advanced NSCLCBiomarkersImmunotherapies

High tumour mutational burden was associated with more frequent and earlier immune-related adverse events in advanced NSCLC

B. Ricciuti

Sep 28 2026

RESEARCH

Resectable NSCLCImmunotherapies

AEGEAN’s second interim analysis kept the EFS benefit of perioperative durvalumab, on an OS reading that crosses 1

M. ReckM. Hochmair

Sep 26 2026

RESEARCH

Advanced NSCLCImmunotherapies

Incidental thymic radiation dose was independently associated with metastasis and death in 1107 patients with NSCLC

B. Ricciuti

Sep 15 2026

CONGRESS

Advanced NSCLCImmunotherapies

HARMONi-2: ivonescimab extends overall survival over pembrolizumab in China

Sep 15 2026

CONGRESS

Advanced NSCLCBiomarkersResectable NSCLC

WCLC 2026, day 4: tumour budding, BRAF class II and III, brain radiotherapy timing, and mobile CT screening

Sep 13 2026

CONGRESS

Advanced NSCLCSCLCADCs

WCLC 2026, day 2: MRI surveillance without prophylactic cranial irradiation, and two relapse trials at 13.3 and 18.5 months

Sep 13 2026

CONGRESS

Advanced NSCLCADCsImmunotherapies

EVOKE-03: sacituzumab govitecan plus pembrolizumab misses both primary endpoints

G. Mountzios

Sep 12 2026

CONGRESS

Advanced NSCLCResectable NSCLCSCLC

WCLC 2026, day 1: extended-interval and subcutaneous dosing in SCLC, and a 70% early response

Sep 10 2026

INDUSTRY NEWS

SCLCImmunotherapies

Tarlatamab added to durvalumab maintenance improved OS in extensive-stage SCLC

Sep 09 2026

INDUSTRY NEWS

Advanced NSCLCImmunotherapies

HARMONi: ivonescimab plus chemotherapy gave 6.8 against 4.4 months PFS after EGFR TKI progression

Sep 08 2026

RESEARCH

Advanced NSCLCImmunotherapies

Pleural metastases carried worse two-year survival than contralateral lung metastases in stage M1a NSCLC

L. Hendriks

Sep 03 2026

INDUSTRY NEWS

Advanced NSCLCImmunotherapies

Akeso reports an OS benefit for ivonescimab over pembrolizumab in PD-L1-positive NSCLC

Sep 02 2026

RESEARCH

Advanced NSCLCImmunotherapies

AI-HOPE registry recruits 920 patients to build machine-learning models for metastatic NSCLC outcomes

R. FerraraL. Hendriks

Aug 27 2026

RESEARCH

Advanced NSCLCADCsImmunotherapies

Two EORTC questionnaires cover the common side effects in NSCLC labels, and miss 62 rarer ones

J. RemonR. Ferrara

Aug 25 2026

RESEARCH

Advanced NSCLCBiomarkersImmunotherapies

Cleared ctDNA within weeks predicted longer survival on immunotherapy in a 109-patient study

P. Forde

Aug 21 2026

RESEARCH

Advanced NSCLCBiomarkersImmunotherapies

A ctDNA tumour fraction of 5% or more marks who benefits from adding chemotherapy to checkpoint blockade

D. Planchard

Aug 19 2026

RESEARCH

BiomarkersResectable NSCLCImmunotherapies

AIOT expert panel endorses chemo-immunotherapy as a new standard in resectable stage II-III NSCLC

T. CasconeP. FordeA. Passaro

Aug 13 2026

RESEARCH

BiomarkersResectable NSCLCImmunotherapies

Pre-surgical ctDNA clearance reached 66% with neoadjuvant nivolumab against 38% with placebo in CheckMate 77T

T. Cascone

Aug 09 2026

RESEARCH

Advanced NSCLCImmunotherapies

Radiation plus durvalumab without chemotherapy cleared its survival target in frail LA-NSCLC patients

C. Rudin

Aug 05 2026

RESEARCH

Advanced NSCLCImmunotherapies

AdvanTIG-301 closed early with 63 patients, leaving its stage III NSCLC comparisons descriptive

S. Peters

Industry Sponsored

Featured Sessions

May 04 2026

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro